Zambia’s HIV treatment network, once a model of global health cooperation, is unraveling after U.S. cuts to PEPFAR. In Mpongwe, a 37‑year‑old security guard died of AIDS, his X‑ray showing advanced infection. Four of eight men in the ward now have AIDS, up from one or two cases a year ago in the region today.

U.S. aid previously supplied 1.3 million patients with free antiretrovirals and a network of 2,885 clinics. After the Trump administration’s restructuring, Zambia kept the basics but discarded prevention services like index testing that identified 70% of new infections. Testing now relies on patient‑initiated requests, risking delayed diagnoses in Southern Africa patients must seek care soon.

Zambia’s health ministry estimates 100,000 people stopped treatment during the upheaval, with 40,000 yet to be re‑engaged. The loss of community‑based drug distribution and mobile outreach has left gaps in adherence. Health officials warn that without sustained U.S. funding, rising infection rates could reverse gains made since 2003 for the next five years and beyond.

An April 30 deadline looms for Zambia to accept a new funding deal tied to expanded U.S. access to mineral resources. Failure to sign could cut all HIV aid, a scenario health officials say would be disastrous. Meanwhile, patients like Lewis Chifuta face prolonged illness, underscoring the human cost of policy shifts for the future.